Ravi Salgia to Exons
This is a "connection" page, showing publications Ravi Salgia has written about Exons.
Connection Strength
1.772
-
Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring MET exon 14 mutation: a research report. Cold Spring Harb Mol Case Stud. 2020 12; 6(6).
Score: 0.588
-
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping. Cancer Treat Rev. 2020 Jul; 87:102022.
Score: 0.561
-
MET in the Driver's Seat: Exon 14 Skipping Mutations as Actionable Targets in Lung Cancer. J Thorac Oncol. 2016 09; 11(9):1381-3.
Score: 0.437
-
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015 Aug; 5(8):850-9.
Score: 0.100
-
Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res. 2009 Sep 15; 15(18):5714-23.
Score: 0.067
-
Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions. Cancer Res. 2011 Apr 01; 71(7):2423-7.
Score: 0.019